Protagonist

PTGX NASDAQ
11.90
+0.04
+0.34%
盘后: 12.00 +0.1 +0.84% 16:00 06/18 EDT
开盘
12.02
昨收
11.86
最高
12.14
最低
11.78
成交量
7.46万
成交均量(3M)
21.48万
52周最高
14.36
52周最低
5.49
换手率
0.32%
市值
2.78亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Protagonist PTGX股票价格,Protagonist股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company's product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs. PTG-100 is an oral, alpha-4-beta-7 (a4b7) integrin-specific antagonist peptide product candidate, which has completed a Phase I clinical trial in normal healthy volunteers (NHVs). PTG-100 is being developed for treatment of moderate-to-severe ulcerative colitis (UC). PTG-200 is an oral Interleukin-23 receptor (IL-23R) antagonist being developed for moderate-to-severe Crohn's disease (CD). PTG-200 is in investigational new drug (IND) enabling studies. PTG-300 is an injectable hepcidin mimetic for treatment of iron overload related rare diseases.
展开 >

最近浏览

名称
价格
涨跌幅